|
Market Closed -
TEL AVIV STOCK EXCHANGE
14:44:01 23/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 2,397.00 ILa | -0.83% |
|
-1.88% | +6.06% |
| 10-06 | Kamada Launches Ustekinumab, Enoxaparin Biosimilars in Israel | MT |
| 10-06 | Kamada Ltd. Announces Expansion of Biosimilars Portfolio with Launch of Two Additional Products in Israel | CI |
| Market Cap | 1.38B 0 445M 398M 368M 333M 623M 42.29B 633M 4.42B 1.75B 22.16B 1.67B 1.64B 69.86B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 1.38B 0 445M 398M 368M 333M 623M 42.29B 633M 4.42B 1.75B 22.16B 1.67B 1.64B 69.86B | EV / Sales 2026 * |
2.27x | EV / Sales 2027 * | 2.02x |
| Free-Float |
54.72% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
TEL AVIV STOCK EXCHANGE
| KMDA | Delayed | |
Nasdaq
| KMDA | Delayed | |
|
CBOE
| KMDA | Real-time |
Last Transcript: Kamada Ltd.
| 1 day | -0.83% | ||
| 1 week | -1.88% | ||
| Current month | -9.55% | ||
| 1 month | -10.09% | ||
| 3 months | +10.97% | ||
| 6 months | -1.92% | ||
| Current year | +6.06% |
| 1 week | 2,349 |  | 2,499 |
| 1 month | 2,300 | | 2,691 |
| Current year | 2,013 | | 2,890 |
| 1 year | 1,956 | | 2,890 |
| 3 years | 1,685 | | 3,045 |
| 5 years | 1,309 | | 3,045 |
| 10 years | 1,309 | | 4,500 |
| Manager | Title | Age | Since |
|---|---|---|---|
Amir London
CEO | Chief Executive Officer | 58 | 01/07/2015 |
Chaime Orlev
DFI | Director of Finance/CFO | 56 | 31/12/2017 |
Eran Nir
COO | Chief Operating Officer | 54 | 01/11/2016 |
| Director | Title | Age | Since |
|---|---|---|---|
David Tsur
BRD | Director/Board Member | 75 | 13/12/1990 |
Leon Recanati
CHM | Chairman | 77 | 07/03/2013 |
| Chairman | 55 | 12/08/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 14/09/26 | Exercice | VP Quality | 61,323 | 0.1063% | ||
| 14/09/26 | Sell | Founder | -22,827 | 0.0396% | ||
| 14/09/26 | Exercice | General Counsel | 23,459 | 0.0407% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.83% | -1.88% | +7.20% | +37.92% | 445M | |
| -2.54% | +1.31% | +54.27% | +117.14% | 1,135B | |
| -1.42% | +3.23% | +38.56% | +74.05% | 635B | |
| +0.16% | +0.08% | +25.29% | +96.64% | 505B | |
| -0.31% | +3.09% | +44.14% | +64.55% | 378B | |
| -1.34% | -0.47% | +66.04% | +40.18% | 358B | |
| -0.68% | +2.65% | +22.98% | +49.15% | 295B | |
| -1.20% | +3.04% | +2.33% | +21.60% | 266B | |
| -1.79% | +1.57% | +50.56% | +61.40% | 237B | |
| -0.73% | -0.10% | +29.02% | +99.06% | 193B | |
| Average | -1.07% | +1.25% | +34.04% | +66.17% | 400.41B | |
| Weighted average by Cap. | -1.35% | +1.63% | +41.02% | +80.32% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 609M 0 196M 175M 162M 147M 274M 18.6B 279M 1.95B 770M 9.75B 735M 720M 30.73B | 685M 0 221M 197M 182M 165M 309M 20.95B 314M 2.19B 868M 10.98B 828M 811M 34.61B |
| Net income | 83.39M 0 26.85M 23.98M 22.15M 20.08M 37.56M 2.55B 38.18M 267M 106M 1.34B 101M 98.64M 4.21B | 101M 0 32.63M 29.14M 26.92M 24.39M 45.64M 3.1B 46.39M 324M 128M 1.62B 122M 120M 5.12B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/10/26 | ILA 2,397.00 | -0.83% | 12,597 |
| 22/10/26 | ILA 2,417.00 | -0.21% | 22,152 |
| 21/10/26 | ILA 2,422.00 | -0.41% | 43,458 |
| 20/10/26 | ILA 2,432.00 | +2.83% | 47,991 |
| 19/10/26 | ILA 2,365.00 | -3.19% | 147,171 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- KMDA Stock
Select your edition
All financial news and data tailored to specific country editions
